[Federal Register Volume 72, Number 111 (Monday, June 11, 2007)]
[Notices]
[Page 32123]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 07-2866]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) and the Assistant Secretary for Health have taken final action in 
the following case:
    Wei Jin, Colorado State University: Based on an investigation 
conducted by Colorado State University (CSU) and additional analysis 
and information obtained by the Office of Research Integrity during its 
oversight review, the U.S. Public Health Service (PHS) found that Mr. 
Wei Jin, former doctoral candidate, Department of Chemistry, CSU, 
engaged in research misconduct in research funded by National Cancer 
Institutes (NCI), National Institutes of Health (NIH), grant R01 
CA85419.
    Specifically, Mr. Jin falsified data/results by claiming he had 
performed a novel total synthesis of renieramycin G, when in fact, he 
obtained renieramycin G through a relatively simple reaction sequence 
from renieramycin M, a natural product that was a gift to the 
laboratory and that had been isolated by others from the Thai sponge. 
Mr. Jin included the falsified data/results in:
     His research notebooks and other records of his research;
     His dissertation, ``Asymmetric total synthesis of (-)-
Reineramycin G and studies toward the total synthesis of Ecteinascidin-
743'';
     A manuscript, Jin, W. & Williams, R., ``Asymmetric total 
synthesis of (-)-Renieramycin G,'' accepted by the Journal of the 
American Chemical Society; and
     Supplemental information relative to the manuscript to be 
published online.
    ORI has implemented the following administrative actions for a 
period of three (3) years, beginning on May 8, 2007:
    (1) Mr. Jin is debarred from eligibility for any contracting or 
subcontracting with any agency of the United States Government and from 
eligibility or involvement in nonprocurement programs of the United 
States Government referred to as ``covered transactions'' as defined in 
HHS' implementation of OMB Guidelines to Agencies on Government-wide 
Debarment and Suspension at 2 CFR Part 376, et seq.; and
    (2) Mr. Jin is prohibited from serving in any advisory capacity to 
PHS, including but not limited to service on any PHS advisory 
committee, board, and/or peer review committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative 
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 
750, Rockville, MD 20852, (240) 453-8800.

John Dahlberg,
Acting Director, Office of Research Integrity.
[FR Doc. 07-2866 Filed 6-8-07; 8:45 am]
BILLING CODE 4150-31-M